GR3034814T3 - Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid - Google Patents

Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid

Info

Publication number
GR3034814T3
GR3034814T3 GR20000402501T GR20000402501T GR3034814T3 GR 3034814 T3 GR3034814 T3 GR 3034814T3 GR 20000402501 T GR20000402501 T GR 20000402501T GR 20000402501 T GR20000402501 T GR 20000402501T GR 3034814 T3 GR3034814 T3 GR 3034814T3
Authority
GR
Greece
Prior art keywords
crystal modification
trifluoromethylphenyl
methylisoxazole
lines
carboxamid
Prior art date
Application number
GR20000402501T
Other languages
Greek (el)
English (en)
Inventor
Holger Dr Faasch
Udo Dr Hedtmann
Uwe Dr Westenfelder
Erich Dr Paulus
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of GR3034814T3 publication Critical patent/GR3034814T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GR20000402501T 1997-08-08 2000-11-10 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid GR3034814T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
GR3034814T3 true GR3034814T3 (en) 2001-02-28

Family

ID=26038983

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000402501T GR3034814T3 (en) 1997-08-08 2000-11-10 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamid

Country Status (28)

Country Link
US (5) US6060494A (cg-RX-API-DMAC10.html)
EP (2) EP0903345B1 (cg-RX-API-DMAC10.html)
JP (2) JPH11124372A (cg-RX-API-DMAC10.html)
KR (2) KR100544041B1 (cg-RX-API-DMAC10.html)
CN (2) CN1181064C (cg-RX-API-DMAC10.html)
AR (1) AR015418A1 (cg-RX-API-DMAC10.html)
AT (2) ATE207065T1 (cg-RX-API-DMAC10.html)
AU (1) AU752764B2 (cg-RX-API-DMAC10.html)
BR (1) BR9806568A (cg-RX-API-DMAC10.html)
CA (1) CA2245267C (cg-RX-API-DMAC10.html)
CZ (3) CZ301426B6 (cg-RX-API-DMAC10.html)
DE (2) DE59800287D1 (cg-RX-API-DMAC10.html)
DK (2) DK0903345T3 (cg-RX-API-DMAC10.html)
ES (2) ES2166205T3 (cg-RX-API-DMAC10.html)
GR (1) GR3034814T3 (cg-RX-API-DMAC10.html)
HK (1) HK1049481B (cg-RX-API-DMAC10.html)
HU (2) HU225870B1 (cg-RX-API-DMAC10.html)
ID (1) ID20667A (cg-RX-API-DMAC10.html)
IL (1) IL125671A (cg-RX-API-DMAC10.html)
NO (1) NO310871B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ331270A (cg-RX-API-DMAC10.html)
PL (1) PL192126B1 (cg-RX-API-DMAC10.html)
PT (2) PT987256E (cg-RX-API-DMAC10.html)
RU (1) RU2224753C2 (cg-RX-API-DMAC10.html)
SK (2) SK282641B6 (cg-RX-API-DMAC10.html)
TR (2) TR200600582A1 (cg-RX-API-DMAC10.html)
TW (1) TW593288B (cg-RX-API-DMAC10.html)
UA (1) UA54411C2 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US7022725B2 (en) * 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2004080461A2 (en) * 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体(上海)有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
LT2262790T (lt) * 2008-03-10 2017-08-25 Takeda Pharmaceutical Company Limited Benzimidazolo junginio kristalas
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
NL178596C (nl) * 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
GB9115377D0 (en) * 1991-07-17 1991-09-04 Rhone Poulenc Agriculture New compositions of matter
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2124800T3 (es) * 1993-01-08 1999-02-16 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
ATE174219T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
TW314467B (cg-RX-API-DMAC10.html) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
PT787491E (pt) * 1994-10-17 2000-11-30 Aventis Pharma Ltd Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
EP1257270B1 (en) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
ID20667A (id) 1999-02-11
DK0903345T3 (da) 2000-10-23
RU2224753C2 (ru) 2004-02-27
CN1373126A (zh) 2002-10-09
US6552202B2 (en) 2003-04-22
TR200600582A1 (tr) 2006-08-21
CZ292943B6 (cs) 2004-01-14
KR100544041B1 (ko) 2006-09-18
PL192126B1 (pl) 2006-09-29
CN1089759C (zh) 2002-08-28
ATE207065T1 (de) 2001-11-15
NZ331270A (en) 2000-04-28
US20040204465A1 (en) 2004-10-14
DE59801792D1 (de) 2001-11-22
HU0700190D0 (en) 2007-05-02
TR199801513A3 (tr) 1999-02-22
DE59800287D1 (de) 2000-11-09
ES2150808T3 (es) 2000-12-01
HUP9801844A3 (en) 2000-04-28
AU7887098A (en) 1999-02-18
CA2245267A1 (en) 1999-02-08
HU229232B1 (en) 2013-09-30
US6900334B2 (en) 2005-05-31
HU225870B1 (en) 2007-11-28
HU9801844D0 (en) 1998-10-28
NO310871B1 (no) 2001-09-10
CZ301514B6 (cs) 2010-03-31
US20030027851A1 (en) 2003-02-06
ATE196764T1 (de) 2000-10-15
SK285216B6 (sk) 2006-09-07
CA2245267C (en) 2008-12-23
TR199801513A2 (xx) 1999-02-22
PT987256E (pt) 2002-03-28
KR100588254B1 (ko) 2006-06-12
NO983632D0 (no) 1998-08-07
US20030166945A1 (en) 2003-09-04
HUP9801844A2 (hu) 2000-02-28
KR19990023433A (ko) 1999-03-25
KR20050077498A (ko) 2005-08-02
UA54411C2 (uk) 2003-03-17
PT903345E (pt) 2001-01-31
PL327901A1 (en) 1999-02-15
EP0987256A1 (de) 2000-03-22
IL125671A0 (en) 1999-04-11
CN1181064C (zh) 2004-12-22
CZ301426B6 (cs) 2010-02-24
BR9806568A (pt) 2000-05-16
EP0987256B1 (de) 2001-10-17
DK0987256T3 (da) 2002-02-11
CZ246898A3 (cs) 1999-02-17
ES2166205T3 (es) 2002-04-01
US6995272B2 (en) 2006-02-07
HK1017681A1 (en) 1999-11-26
SK105898A3 (en) 1999-02-11
CN1208034A (zh) 1999-02-17
US6060494A (en) 2000-05-09
US6221891B1 (en) 2001-04-24
SK282641B6 (sk) 2002-10-08
JP2009280604A (ja) 2009-12-03
EP0903345A1 (de) 1999-03-24
AR015418A1 (es) 2001-05-02
AU752764B2 (en) 2002-09-26
EP0903345B1 (de) 2000-10-04
HK1049481A1 (en) 2003-05-16
JPH11124372A (ja) 1999-05-11
IL125671A (en) 2002-11-10
HK1049481B (zh) 2005-07-08
NO983632L (no) 1999-02-09
TW593288B (en) 2004-06-21

Similar Documents

Publication Publication Date Title
HU9801844D0 (en) Crystalline form of n-(4-trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
WO2000003749A3 (en) Method for regulating hair growth
AU6613896A (en) Chemical compounds
NO993247D0 (no) FremgangsmÕte for fremstilling av tolterodin
AU1497797A (en) An improved closed loop single mixed refrigerant process
AU1926197A (en) Preparation containing a combination of 5-methylisoxazole-4 -carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
WO1999057751A3 (en) Method and apparatus for controlling the radial temperature gradient of a wafer while ramping the wafer temperature
AU2675095A (en) Indol derivatives useful for the treatment of migraine, composition and utilization
NO902301L (no) Fremgangsmaate for fremstilling av diarylstyrylkinolin-disyrer.
NO20002676D0 (no) Androgene steroidforbindelser og en fremgangsmÕte for fremstilling og anvendelse av samme
NO984344L (no) Ny asymmetriske syntese av R-<alfa>-propylpiperonyalamin og dets analoger
IT1271277B (it) Procedimento per l'attuazione di un ciclo di avvolgimento flessibile e modulante,ed apparecchiatura adatta allo scopo
AU754616C (en) N-(phenylsulfonyl) picolinamide derivatives, process for producing the same, and herbicide
MX9100560A (es) Integron de corinebacterias,procedimiento para la transformacion corinebacteria mediante dicho integron y corinebacteria obtenida
AU7610781A (en) 4h-3,1-benzoxazine
GR3005254T3 (cg-RX-API-DMAC10.html)
AU1512097A (en) Process for the preparation of unsymmetrical 4,6-bis(aryloxy)pyriidine compounds
NO20000182L (no) Fremgangsmåte for fremstilling av alkoksyfuranonamin- derivater, forbindelser frembragt ved fremgangsmåten og anvendelse av disse forbindelser
PT98268A (pt) Processo para a preparacao de indano-pirrolidino-carbamatos
EP1116720A4 (en) PROCESS FOR THE PREPARATION OF ISOCHROMANONES AND INTERMEDIATES USED FOR THEIR PREPARATION
IT1278045B1 (it) Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di
AU3114197A (en) New use of derivatives of cystine
FI972675L (fi) 3,3-(disubstituoitu)sykloheksan-1-oni-monomeerejä ja vastaavia yhdisteitä
AR242791A1 (es) Nuevos compuestos derivados de las 2-(6 fluoruro-3h-benzotiazolon-5-ilo-4,5,6,7-tetrahidro-2h-isoindol-1,3-dionas, utiles como herbicidas, procedimiento para obtenerlos.
AU2933199A (en) Process for the preparation of sulphonated distyryl-biphenyl compounds